Cargando…

2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan

BACKGROUND: Antibiotics are often inappropriately prescribed for treating upper respiratory infection (URI) patients in ambulatory care settings. In Japan, a previous study estimated physicians prescribed antibiotics in about 30% of URI cases. However, trends of prescription behavior and additional...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuzuki, Shinya, Kimura, Yuki, Ishikane, Masahiro, Kusama, Yoshiki, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810315/
http://dx.doi.org/10.1093/ofid/ofz360.1881
_version_ 1783462220937560064
author Tsuzuki, Shinya
Kimura, Yuki
Ishikane, Masahiro
Kusama, Yoshiki
Ohmagari, Norio
author_facet Tsuzuki, Shinya
Kimura, Yuki
Ishikane, Masahiro
Kusama, Yoshiki
Ohmagari, Norio
author_sort Tsuzuki, Shinya
collection PubMed
description BACKGROUND: Antibiotics are often inappropriately prescribed for treating upper respiratory infection (URI) patients in ambulatory care settings. In Japan, a previous study estimated physicians prescribed antibiotics in about 30% of URI cases. However, trends of prescription behavior and additional costs of inappropriate antibiotic use in URI cases are still not clear in Japan. The present study’s main objective was to clarify the amount of additional cost owing to inappropriate antibiotic prescription for URI, and the recent trend. METHODS: We conducted a retrospective observational survey using longitudinal claims data spanning 2013–2016, obtained from the Japan Medical Data Center Co., Ltd. (JMDC) Claims Database, which contains anonymous claim data on 5.1 million (for 2013–2016) corporate employees covered by the employees’ health insurance plan (Social insurance), and their family members <65 years old. Six physicians specialized in infectious disease assessed the appropriateness of antibiotic prescription based on the ICD-10 code in the database. The total additional cost of antibiotic prescription for URI at the national level was estimated by weighting corresponds to the age-structured population data, from the healthcare payer perspective. Costs of treatment for adverse events and of antimicrobial resistance caused by inappropriate antibiotic prescription were not taken into consideration. RESULTS: The total annual cost of antibiotic prescription for URI was estimated at US$423.6 (95% confidence interval: 416.8–430.5) million in 2013, $340.9 (335.7–346.2) million in 2014, $349.9 (344.5–355.3) million in 2015, and $297.1 (292.4–301.9) million in 2016. CONCLUSION: Although a decreasing trend was observed, the annual cost of antibiotic prescription for URI potentially imposes a substantial economic burden in Japan. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810315
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68103152019-10-28 2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan Tsuzuki, Shinya Kimura, Yuki Ishikane, Masahiro Kusama, Yoshiki Ohmagari, Norio Open Forum Infect Dis Abstracts BACKGROUND: Antibiotics are often inappropriately prescribed for treating upper respiratory infection (URI) patients in ambulatory care settings. In Japan, a previous study estimated physicians prescribed antibiotics in about 30% of URI cases. However, trends of prescription behavior and additional costs of inappropriate antibiotic use in URI cases are still not clear in Japan. The present study’s main objective was to clarify the amount of additional cost owing to inappropriate antibiotic prescription for URI, and the recent trend. METHODS: We conducted a retrospective observational survey using longitudinal claims data spanning 2013–2016, obtained from the Japan Medical Data Center Co., Ltd. (JMDC) Claims Database, which contains anonymous claim data on 5.1 million (for 2013–2016) corporate employees covered by the employees’ health insurance plan (Social insurance), and their family members <65 years old. Six physicians specialized in infectious disease assessed the appropriateness of antibiotic prescription based on the ICD-10 code in the database. The total additional cost of antibiotic prescription for URI at the national level was estimated by weighting corresponds to the age-structured population data, from the healthcare payer perspective. Costs of treatment for adverse events and of antimicrobial resistance caused by inappropriate antibiotic prescription were not taken into consideration. RESULTS: The total annual cost of antibiotic prescription for URI was estimated at US$423.6 (95% confidence interval: 416.8–430.5) million in 2013, $340.9 (335.7–346.2) million in 2014, $349.9 (344.5–355.3) million in 2015, and $297.1 (292.4–301.9) million in 2016. CONCLUSION: Although a decreasing trend was observed, the annual cost of antibiotic prescription for URI potentially imposes a substantial economic burden in Japan. [Image: see text] [Image: see text] [Image: see text] [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810315/ http://dx.doi.org/10.1093/ofid/ofz360.1881 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Tsuzuki, Shinya
Kimura, Yuki
Ishikane, Masahiro
Kusama, Yoshiki
Ohmagari, Norio
2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan
title 2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan
title_full 2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan
title_fullStr 2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan
title_full_unstemmed 2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan
title_short 2201. Cost of Antimicrobial Use Against Upper Respiratory Infection in Japan
title_sort 2201. cost of antimicrobial use against upper respiratory infection in japan
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810315/
http://dx.doi.org/10.1093/ofid/ofz360.1881
work_keys_str_mv AT tsuzukishinya 2201costofantimicrobialuseagainstupperrespiratoryinfectioninjapan
AT kimurayuki 2201costofantimicrobialuseagainstupperrespiratoryinfectioninjapan
AT ishikanemasahiro 2201costofantimicrobialuseagainstupperrespiratoryinfectioninjapan
AT kusamayoshiki 2201costofantimicrobialuseagainstupperrespiratoryinfectioninjapan
AT ohmagarinorio 2201costofantimicrobialuseagainstupperrespiratoryinfectioninjapan